Improving immune cell recruitment in cancer treatment
Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs
This study is looking at a new way to boost the immune system's fight against tumors by using a special vaccine and a medication called dasatinib for patients who haven't had success with regular treatments, hoping to help more immune cells reach and attack the tumors.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10916167 on NIH RePORTER |
What this research studies
This research investigates how chemokines, which are signaling proteins, can be manipulated to enhance the immune response against tumors. By using a combination vaccine that targets specific tumor vascular antigens, the study aims to increase the infiltration of protective immune cells into the tumor microenvironment. The approach includes administering this vaccine alongside a medication called dasatinib to patients who have not responded to standard immunotherapy. The goal is to promote the formation of structures that help in the immune response and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced-stage melanoma who have shown resistance to existing immunotherapies.
Not a fit: Patients with early-stage cancer or those who have not yet undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments by enhancing the body's immune response against tumors.
How similar studies have performed: Previous research has shown promising results with similar approaches, indicating potential for significant advancements in cancer treatment.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Storkus, Walter J. — Roswell Park Cancer Institute Corp
- Study coordinator: Storkus, Walter J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.